Navigation Links
Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
Date:7/6/2010

XIANYANG, China, July 6 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) ("Biostar" or "the Company"), the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin-Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, today announced that Mr. Deyin "Bill" Chen has been appointed Chief Financial Officer, effective July 1, 2010. Mr. Chen replaces Ms. Elaine Zhao, who resigned effective at the close of business on June 30, 2010.

Mr. Chen brings more than 13 years of multinational and Big 4 accounting experiences to Biostar. His expertise includes financial management, financing transactions, corporate governance and investor relations. Most recently, Mr. Chen was an independent advisor engaged in local RMB PE fundraising and providing M&A and PE advisory and due diligence services. Prior to that, Mr. Chen was a partner of Trenwith Securities LLC, where he was engaged in and executed cross-border equity financing for various Chinese companies. He was also a senior business advisor of Ernst & Young and a senior financial advisor of IBM Global Services. From 1997 to 2000, Mr. Chen was the CFO for China Operations of Ashland Inc.

Mr. Chen graduated with a Bachelor's degree in Nuclear Physics from Fudan University, and Master of Science degree in Nuclear Engineering and Accountancy from University of Cincinnati. He also holds a MBA degree from York University.

"We are very pleased to have Bill join us as our Chief F
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line
2. Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results
3. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
4. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
5. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
6. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
7. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
8. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
9. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
10. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
11. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , AURORA, Ontario, Sept. 8 Helix BioPharma Corp. (TSX, ... announced private placement of 6,625,000 units at $2.05 per unit. ... and one common share purchase warrant, with each common share purchase warrant ... the Company at a price of $2.87 for up to three years ...
... , CAMBRIDGE, Mass., Sept. 8 ... the development of next-generation cellulosic ethanol and high-performance specialty enzymes, ... of the Company,s common stock will take effect after market ... continue to trade on the NASDAQ Global Market under the ...
... , FORT LAUDERDALE, Fla., Sept. 8 South Florida ... launched an important joint event with the state,s life sciences organization, ... Lauderdale on August 27, to hear experts from Scripps Florida, University ... and information technology. , , Presentations ...
Cached Biology Technology:Helix BioPharma Closes Private Placement 2Helix BioPharma Closes Private Placement 3Verenium Announces Reverse Stock Split to Take Effect September 9 2Verenium Announces Reverse Stock Split to Take Effect September 9 3Verenium Announces Reverse Stock Split to Take Effect September 9 4South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd 2South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd 3
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
(Date:4/17/2014)... and Professor Luca Razzari of the nergie Matriaux ... grants from the John R. Evans Leaders Fund ... the acquisition of state-of-the-art biotech and nanophotonics equipment. ... from the Ministre de l,Enseignement suprieur, de la ... (MESRST). These new laboratories will help us develop ...
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... a protein critical to enabling the brain to talk to ... researchers report. The finding that an antibody to ... brain-muscle interaction helps explain why as many as 10 percent ... muscle weakness, yet their blood provides no clue of the ...
... of brain cell that tamps down stem cell activity ... progeny, Johns Hopkins researchers report. Understanding how these new ... how to behave is of special interest because changes ... as Alzheimer,s, mental illness and aging. "We,ve ...
... have in common? Based on work by scientists at the European ... same part of the brain reacts to both. In a study ... at least in mice different types of fear are ... out those fears in the same way. The findings could have ...
Cached Biology News:New cause found for muscle-weakening disease myasthenia gravis 2New cause found for muscle-weakening disease myasthenia gravis 3SIGNAL found to enhance survival of new brain cells 2What are you scared of? 2
... variety of solvent vapors that can contaminate and ... (GCF400) allows for the collection of liquid into ... cooling time minimizes waiting period., , Easy ... , -50?C Temerature for ...
... Protein Phosphatase-2A (PPase-2A) is a serine/threonine ... It is isolated as the heterodimer of ... has the ability to dephosphorylate the a-subunit ... subunit, PPase-2A has broad substrate specificity and ...
... is a high performance spectral scanning ... incubator. With the advanced SkanIt Software ... for drug discovery assay development. Varioskan ... intensity, time-resolved fluorescence and photometric assays ...
... Effectively condenses and traps a wide variety of ... oil. Easy-to-use glass condensation flask (GCF400) allows for the ... easy draining. Rapid cooling time minimizes waiting period., ... high volatile solvents , ...
Biology Products: